Edwin Reisz Sells 60,769 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 60,769 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $438,144.49. Following the transaction, the insider owned 1,447,057 shares of the company’s stock, valued at $10,433,280.97. This represents a 4.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aveanna Healthcare Price Performance

Shares of AVAH traded up $0.02 during mid-day trading on Thursday, hitting $7.42. 3,877,110 shares of the stock were exchanged, compared to its average volume of 938,081. The company has a market cap of $1.55 billion, a PE ratio of 20.61 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a 52-week low of $3.67 and a 52-week high of $10.32. The firm has a 50-day moving average of $8.48 and a two-hundred day moving average of $8.44. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.

Wall Street Analysts Forecast Growth

AVAH has been the subject of several research reports. William Blair assumed coverage on shares of Aveanna Healthcare in a research report on Monday, December 8th. They set an “outperform” rating for the company. BMO Capital Markets assumed coverage on shares of Aveanna Healthcare in a research report on Thursday, November 13th. They set an “outperform” rating and a $11.00 target price on the stock. UBS Group increased their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Barclays lifted their price target on Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Finally, Truist Financial upped their price objective on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Aveanna Healthcare currently has an average rating of “Hold” and an average price target of $11.06.

Institutional Trading of Aveanna Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in shares of Aveanna Healthcare during the second quarter valued at approximately $43,000. MQS Management LLC purchased a new stake in shares of Aveanna Healthcare in the second quarter worth approximately $59,000. Belvedere Trading LLC bought a new stake in shares of Aveanna Healthcare during the 2nd quarter worth approximately $62,000. Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare during the 2nd quarter worth approximately $64,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Aveanna Healthcare during the 2nd quarter valued at $68,000. Institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.